ANTI DIABETICS

Brand Owner (click to sort) Address Description
ACTOPLUS MET TAKEDA PHARMACEUTICAL COMPANY LIMITED 1-1, Doshomachi 4-chome, Chuo-ku Osaka 541-0045 Japan Anti-diabetics;
ACTOPLUS SULF TAKEDA PHARMACEUTICAL COMPANY LIMITED 1-1, Doshomachi 4-chome, Chuo-ku Osaka 541-0045 Japan Anti-diabetics;SULF;
ACTOS TAKEDA PHARMACEUTICAL COMPANY LIMITED 1-1, Doshomachi 4-chome, Chuo-ku Osaka 541-0045 Japan anti-diabetics;
ACTOS-MET Takeda Chemical Industries, Ltd. 1-1, Doshomachi 4-Chome, Chuo-Ku Osaka Japan Anti-diabetics;ACTOS MET;
ACTOS-SULF Takeda Chemical Industries, Ltd. 1-1, Doshomachi 4-Chome, Chuo-Ku Osaka Japan Anti-diabetics;
ACTOSULF TAKEDA PHARMACEUTICAL COMPANY LIMITED 1-1, Doshomachi 4-chome, Chuo-ku Osaka 541-0045 Japan Anti-diabetics;
GLUSTIN Takeda Chemical Industries, Ltd. 1-1, Doshomachi 4-Chome, Chuo-Ku Osaka Japan anti-diabetics;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.